Lifetime Costs of Complications Resulting From Type 2 Diabetes in the U.S.
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—To model the lifetime costs associated with complications of type 2 diabetes. RESEARCH DESIGN AND METHODS—A cohort of 10,000 patients with diabetes was simulated using a model based on existing epidemiological studies. Complication rates were estimated for various stages of macrovascular disease, nephropathy, retinopathy, neuropathy, and hypoglycemia. At the beginning of the simulation, patients were assumed to have been treated for 5 years and have a mean HbA1c of 8.4. From the U.K. Prospective Diabetes Study, it was estimated that on current therapies, the HbA1c would drift upward on average 0.15% per year. Direct medical costs of managing each complication were estimated (in 2000 U.S. dollars) from all-payor databases, surveys, and literature. RESULTS—Macrovascular disease was estimated to be the largest cost component, accounting for 85% of cumulative costs of complications over the first 5 years. The costs of complications were estimated to be $47,240 per patient over 30 years, on average. The management of macrovascular disease is estimated to be the largest cost component, accounting for 52% of the costs; nephropathy accounts for 21%, neuropathy accounts for 17%, and retinopathy accounts for 10% of the costs of complications. CONCLUSIONS—The complications of diabetes account for substantial costs, with management of macrovascular disease being the largest and earliest. If improving glycemic control prevents complications, it will reduce these costs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Harris, M. I., Flegal, K. M., Cowie, C. C., Eberhardt, M. S., Goldstein, D. E., Little, R. R., Wiedmeyer, H.-M., & Byrd-Holt, D. D. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.518 · Cited by 2,703
Gerstein, H. C. (2001) · JAMA · doi:10.1001/jama.286.4.421 · Cited by 2,440
Microalbuminuria Predicts Clinical Proteinuria and Early Mortality in Maturity-Onset Diabetes
Mogensen, C. E. (1984) · New England Journal of Medicine · doi:10.1056/nejm198402093100605 · Cited by 1,908
Long-Term Complications of Diabetes Mellitus
Nathan, D. M. (1993) · New England Journal of Medicine · doi:10.1056/nejm199306103282306 · Cited by 1,495
Glucose Tolerance and Cardiovascular Mortality: Comparison of Fasting and 2-Hour Diagnostic Criteria
(2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.3.397 · Cited by 1,371
(1999) · The Lancet · doi:10.1016/s0140-6736(98)12131-1 · Cited by 1,313
Borch‐Johnsen, K., Neil, A., Balkau, B., Larsen, S. H., Nissinen, A. E. T., Pekkanen, J., Keinanen-Kiukaanniemi, S. M., Hiltunen, L. A., Kivelä, S., Tuomilehto, J. O., et al. (1999) · The Lancet · Cited by 1,272
Cited by
Epidemiology of Diabetes and Diabetes-Related Complications
Deshpande, A. D., Harris-Hayes, M., & Schootman, M. (2008) · Physical Therapy · doi:10.2522/ptj.20080020 · Cited by 1,773
The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues
Thangarajah, H., Yao, D., Chang, E. I., Shi, Y., Jazayeri, L., Vial, I. N., Galiano, R. D., Du, X.-L., Grogan, R., Galvez, M. G., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906670106 · Cited by 464
The 10-Year Cost-Effectiveness of Lifestyle Intervention or Metformin for Diabetes Prevention
The Diabetes Prevention Program Research Group (2012) · Diabetes Care · doi:10.2337/dc11-1468 · Cited by 436
“The costs of diabetes increase with duration of diabetes and with the presence of complications and comorbidities and would be expected to be lower for persons with short durations of diabetes and for those without complications (22).”
BackgroundLifetime Direct Medical Costs of Treating Type 2 Diabetes and Diabetic Complications
Zhuo, X., Zhang, P., & Hoerger, T. J. (2013) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2013.04.017 · Cited by 272
Guidelines for Computer Modeling of Diabetes and Its Complications
American Diabetes Association Consensus Panel (2004) · Diabetes Care · doi:10.2337/diacare.27.9.2262 · Cited by 270
The Direct Medical Cost of Type 2 Diabetes
Brandle, M., Zhou, H., Smith, B. R. K., Marriott, D., Burke, R., Tabaei, B. P., Brown, M. B., & Herman, W. H. (2003) · Diabetes Care · doi:10.2337/diacare.26.8.2300 · Cited by 269
Pharmacoeconomic Analyses Using Discrete Event Simulation
Caro, J. J. (2005) · PharmacoEconomics · doi:10.2165/00019053-200523040-00003 · Cited by 191
Self-citationScreening for type 2 diabetes mellitus: a cost-effectiveness analysis
Hoerger, T. J., Harris, R., Hicks, K. A., Donahue, K., Sorensen, S., & Engelgau, M. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-9-200405040-00008 · Cited by 178
Medication adherence and glycemic control among newly diagnosed diabetes patients
Lin, L.-K., Sun, Y., Heng, B. H., Chew, D. E. K., & Chong, P.-N. (2017) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2017-000429 · Cited by 123
Ravaut, M., Sadeghi, H., Leung, K. K., Volkovs, M., Kornas, K., Harish, V., Watson, T., Lewis, G. F., Weisman, A., Poutanen, T., et al. (2021) · npj Digital Medicine · doi:10.1038/s41746-021-00394-8 · Cited by 121
Boye, K. S., Thieu, V. T., Lage, M. J., Miller, H., & Paczkowski, R. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02106-4 · Cited by 99
“cular disease has been found to account for 85% of the cumulative costs of complications over a 5-year period among individuals with T2D [30].”
BackgroundStraka, R. J., Liu, L. Z., Girase, P. S., DeLorenzo, A., & Chapman, R. H. (2009) · Cardiovascular Diabetology · doi:10.1186/1475-2840-8-53 · Cited by 67
Cho, J. H., Kim, H.-S., Yoo, S. H., Jung, C. H., Lee, W. J., Park, C. Y., Yang, H. K., Park, J. Y., Park, S. W., & Yoon, K. H. (2017) · Journal of Telemedicine and Telecare · doi:10.1177/1357633x16657500 · Cited by 45
Hertzberg, S. N. W., Jørstad, Ø. K., Petrovski, B. É., Bragadottir, R., Steffensen, L. A., Moe, M. C., Burger, E. A., & Petrovski, G. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph191912603 · Cited by 6
Metadata
- Authors
- Caro, J. J., Ward, A. J., & O’Brien, J. A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2002-03-01
- Volume
- 25
- Issue
- 3
- Pages
- 476-481
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2118095379
- Cited by
- 258
- References
- 43
- FWCI
- 41.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.